V I S I T
WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760
Vol. 36 No.6 • 10/2019
DAILY CLINICAL LAB NEWS
®
I
N
T
E
Whole-Blood Test for Acute Zika Infections ika virus infections are linked to congenital malformations in neonates from mothers infected during pregnancy and to neurologic disorders in adults. Reverse transcription polymerase chain reaction (RT-PCR) is the most reliable method for confirming Zika
Z
R
N
A
T
I
O
Identifying Colorectal Cancer Subtypes Improves Treatment Decisions olorectal cancer is the second leading cause of cancer death in the USA, and is expected to cause over 50,000 deaths in 2019, but until now, it was unclear which drugs were most effective for which patients. Consensus Molecular Subtype
C
categorizes colorectal cancer into four distinct biologically characterized subgroups based on how mutations in the tumor behave. The subgroups were created using data from several teams around the world that had previously analyzed tumors of colorectal cancer
Cont’d on page 5
Cont’d on page 6
Biomarker Panel Accurately Predicts Risk of Mortality
A
L
Improved Test for Ovarian Cancer varian cancer is often discovered at a late stage and has a high mortality rate. Overall 5-year survival is expected at 30% to 40% after treatment, and there has been no test specific enough to justify screening. Women with accidental findings of an ovarian cyst or with symptoms instead undergo ultrasound and if abnormalities are seen, surgery is the only way to
O
Cont’d on page 7
Test Indicates Need For Chemotherapy nvasive lobular carcinoma (ILC) is the most common special type of breast cancer, and is characterized by functional loss of Ecadherin, resulting in cellular adhesion defects. ILC typically present as estrogen receptor positive, grade 2 breast cancers, with a good short-term prognosis. Many of the clinical challenges associated with diagnosing and managing patients with ILC
I
eriatrics researchers used advanced metabolomic techniques to identify a panel of 14 biomarkers that can predict 5-10 year mortality risk with a high degree of accuracy. By segmenting patients at higher risk, the blood-based test panel can improve healthcare and extend lives.
G Image: Courtesy of iQ Group Global
N
Cont’d on page 4
Cont’d on page 6 V
I
S
I
T
LINKXPRESS COM R E A D E R
S E R V I C E
®
Study Urges Wider Use of C-Reactive Protein Point-of-Care Testing
INSIDE
-Reactive Protein (CRP) testing in point-of-care (POC) or other primary settings, can help reduce diagnostic uncertainty by differentiating between bacterial and viral infections, and has been shown to be cost-effective toward reducing inappropriate
Clinical News . . . 4-18 IFCC News . . . . . . 19 Product News . .10-18 Industry News . . . . 25 Events Calendar . . 26
P O R T A L
Renew /Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information:
C
Cont’d on page 4
Alzheimer’s Stratified by Apolipoprotein E Genotype
Identify LinkXpress codes of 1 interest as you read magazine ®
on LinkXpress.com 2 Click to reach reader service portal
3
Mark code(s) of interest on LinkXpress ® inquiry matrix
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
lzheimer’s disease (AD) is a chronic neurodegenerative disease that usually starts slowly and gradually worsens over time. It is the cause of 60% to 70% of cases of dementia. Apolipoprotein E (APOE) is a protein involved in the metabo-
A
PUBLISHED IN COOPERATION WITH
lism of fats in the body. It is implicated in Alzheimer’s disease and cardiovascular disease. The gene, APOE, is mapped to chromosome 19 in a cluster with apolipoprotein C1 (APOC-I) and the apolipoprotein C2 (APOC-2). An international team of scientists led Cont’d on page 6
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<